CELU

CELU

USD

Celularity Inc. Class A Common Stock

$1.610-0.020 (-1.227%)

即時價格

Healthcare
生物科技
美國

價格圖表

關鍵指標

市場指標
公司基本面
交易統計

市場指標

開盤

$1.630

最高

$1.670

最低

$1.500

交易量

0.00M

公司基本面

市值

40.2M

行業

生物科技

國家

United States

交易統計

平均交易量

0.15M

交易所

NCM

貨幣

USD

52週範圍

最低 $1.001當前 $1.610最高 $5.22

AI分析報告

最後更新: 2025年4月25日
由AI生成數據來源: Yahoo Finance, Bloomberg, SEC

CELU (Celularity Inc. Class A Common Stock): Checking the Pulse on Price and AI Signals

Stock Symbol: CELU Generate Date: 2025-04-25 04:42:17

Let's take a look at what's been going on with Celularity's stock lately, based on the numbers we have.

What's the Buzz? (News Sentiment)

Alright, first off, we don't have any specific news headlines or articles provided right now. So, it's tough to get a feel for the general sentiment or what big events might be impacting the stock price recently. Without news, we're flying a bit blind on the "why" behind the moves.

Checking the Price Tag (Price Action)

Looking back over the last few months of trading data, CELU has seen quite a ride. Back in late January, shares were trading up around the $2.40 to $2.60 mark. Things took a pretty sharp turn lower through February, hitting lows near $1.00 to $1.15 by early March.

Then, we saw a bounce! The price climbed back up, even touching above $2.00 briefly in late March before pulling back again in April. The trading has been a bit choppy, with some days seeing bigger swings than others, though volume hasn't been consistently high except for a few notable spikes.

The last price point we have, from April 24th, shows the stock closing around $1.69. This puts it right in the middle of that recent April trading range, below the late March high but well above the early March lows.

What the AI Model is Seeing (AI Recommendation Insights)

We've got some data from an AI model that gives us a few interesting points to consider, though its confidence level is moderate (around 59%).

  • Mixed Technical Signals: The AI sees some technical indicators pointing in different directions. It notes a potentially bullish trend based on one indicator (DMI), but also a bearish signal from another (MACD). It also flags the current price being close to a support level, which could be seen as a buying chance. So, the technical picture isn't perfectly clear according to this model.
  • Mixed Fundamental Picture: On the company's core health (fundamentals), the AI highlights a few things. It likes the company's high revenue growth (that's a big plus!) and thinks the valuation looks attractive compared to peers, even though the company isn't profitable yet (its P/E is negative, but less negative than the industry average). On the flip side, it points out poor return on equity and, importantly, high debt levels.
  • Risk Factors: The AI correctly flags some key risks here: the stock can be volatile, the company carries high debt relative to its industry, it's a small company (small market cap), and trading volume can be low. These are all things to be aware of.
  • Suggested Levels: Based on its analysis, the AI model suggests potential entry points around $1.65 to $1.70. It sets a potential stop-loss level at $1.52 (a point below which you might consider selling to limit losses) and a potential take-profit level at $1.72 (a point where you might consider selling to lock in gains). It sees this as a potential long-term play (6+ months) suitable for growth or value investors.

Putting It All Together: Outlook & Ideas

Okay, so we don't have news or future price predictions directly, which makes a definitive call tough. However, we can combine the recent price action with the AI's perspective.

The stock has pulled back in April after a March bounce, and it's currently trading right around the levels the AI model identified as potential entry points ($1.65 - $1.70). The AI's analysis is mixed – it sees good growth and potentially attractive valuation but also technical headwinds and significant debt risk.

Given the AI's suggested levels and the current price hovering near them, the model seems to be leaning towards the idea that the current price area might be interesting for those looking at a long-term horizon, despite the risks.

  • Potential Strategy Idea (Based on AI): If you were considering the AI's view, you might look at the current price area (around $1.65 - $1.70) as a potential entry point.
  • Managing Risk (Based on AI): The AI suggests a stop-loss around $1.52. This level is below the recent lows in April and significantly above the early March lows, aiming to limit potential downside if the price continues to fall.
  • Potential Upside Target (Based on AI): The AI's take-profit level is $1.72, which is just slightly above the current price. This suggests the AI sees limited immediate upside from this exact point based on its short-term technical view, or perhaps it's a very conservative target.

Remember, the AI's confidence is moderate, and its signals are mixed. The high debt and volatility are real risks.

Company Snapshot

Just a quick reminder about Celularity itself: It's a clinical-stage biotech company working on cell therapies, which is a cutting-edge but often risky field. They are a small company with significant debt, but they have shown strong revenue growth. Their success heavily depends on their experimental therapies moving through clinical trials.


Disclaimer: This analysis is based solely on the provided data and is for informational purposes only. It is not financial advice. Investing in stocks, especially small-cap biotech companies like CELU, involves significant risk, including the potential loss of your entire investment. Stock prices can be highly volatile. You should always conduct your own thorough research, consider your personal financial situation and risk tolerance, and consult with a qualified financial advisor before making any investment decisions. The AI recommendations mentioned are from a specific model and should not be taken as guaranteed outcomes.

相關新聞

GlobeNewswire

Celularity Receives Nasdaq Notice Regarding Non-Payment of Nasdaq Fees

FLORHAM PARK, N.J., April 25, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity" or the "Company"), a cellular and regenerative medicine company, today announced that Nasdaq has notified the Company

查看更多
Celularity Receives Nasdaq Notice Regarding Non-Payment of Nasdaq Fees

AI預測Beta

AI推薦

看跌

更新於: 2025年4月28日 下午12:20

看跌中立看漲

58.4% 信心度

風險與交易

風險級別4/5
高風險
適合
價值成長
交易指南

入場點

$1.52

獲利了結

$1.64

止損

$1.45

關鍵因素

當前價格比 MA(20) 的 $1.55 高出 3.7%
PDI 39.5 在 MDI 30.8 上方,ADX 17.8,表明看漲趨勢
MACD -0.0083 在信號線 -0.0212 上方,表示看漲交叉

保持更新

設定價格提醒,獲取AI分析更新和即時市場新聞。